Navigating Novel Pathways and Treatment Decisions in IgA Nephropathy - Episode 8
Efficacy and safety may favor B-cell biologics, but route, immunosuppression concerns, and patient preference shape real decisions. The panel also weighs sequencing, kidney protection, and combination approaches for high-risk, inflammatory disease.
Dr. Wadhwani asks Dr. Geara what he weighs most when choosing between an oral targeted therapy and a B-cell biologic. Dr. Geara says physicians prioritize safety, with route of administration a second consideration. For patients, route can matter a great deal. Some have needle phobia, and an injectable biologic provokes real anxiety. Others cannot accept immunosuppression because of their work or their infection risk, and these biologics carry some level of it. In such selected patients an oral option may take priority.
When Dr. Wadhwani asks whether one therapy stands out for a patient with no preference, Dr. Geara answers that across agents the APRIL and BAFF/APRIL class appears superior on efficacy and safety. He would lead with that class and keep other therapies as alternatives.
On sequencing, Dr. Cheung notes that access still limits options in the UK. Dr. Cheung prioritizes drugs that suppress pathogenic IgA production, ideally an APRIL or BAFF/APRIL inhibitor, though targeted-release budesonide can also play a role. Because patients are often diagnosed with stage 3 chronic kidney disease or lower, Dr. Cheung also layers in kidney-protective therapy that can continue for the long term.
Dr. Wadhwani then asks whether combining agents from different pathways is near. Dr. Cheung sees a possible role for patients needing escalation, particularly those with very inflammatory disease and active findings on biopsy. Rapidly progressive patients were excluded from trials and might benefit, but safety of combinations remains unknown. Dr. Wadhwani agrees more data are needed, since each new therapy raises more questions about what to do next.
Up next, in "Emerging B-Cell Therapies and Real-World Evidence in IgAN," Dr. Cheung reviews povetacicept and other pipeline agents, and Dr. Geara explains how much weight real-world data deserve.